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Background: After breast-conserving radiation therapy most patients experience acute skin toxicity to some
degree. This may impair patients’ quality of life, cause pain and discomfort. In this study, we investigated treatment
and patient-related factors, including genetic polymorphisms, that can modify the risk for severe radiation-induced
skin toxicity in breast cancer patients.
Methods: We studied 377 patients treated at Ghent University Hospital and at ST.-Elisabeth Clinic and Maternity in
Namur, with adjuvant intensity modulated radiotherapy (IMRT) after breast-conserving surgery for breast cancer.
Women were treated in a prone or supine position with normofractionated (25 × 2 Gy) or hypofractionated
(15 × 2.67 Gy) IMRT alone or in combination with other adjuvant therapies. Patient- and treatment-related factors
and genetic markers in regulatory regions of radioresponsive genes and in LIG3, MLH1 and XRCC3 genes were
considered as variables. Acute dermatitis was scored using the CTCAEv3.0 scoring system. Desquamation was scored
separately on a 3-point scale (0-none, 1-dry, 2-moist).
Results: Two-hundred and twenty patients (58%) developed G2+ dermatitis whereas moist desquamation occurred
in 56 patients (15%). Normofractionation (both p < 0.001), high body mass index (BMI) (p = 0.003 and p < 0.001), bra
cup size≥D (p = 0.001 and p = 0.043) and concurrent hormone therapy (p = 0.001 and p = 0.037) were significantly
associated with occurrence of acute dermatitis and moist desquamation, respectively. Additional factors associated with
an increased risk of acute dermatitis were the genetic variation in MLH1 rs1800734 (p=0.008), smoking during RT (p =
0.010) and supine IMRT (p = 0.004). Patients receiving trastuzumab showed decreased risk of acute dermatitis (p < 0.001).
Conclusions: The normofractionation schedule, supine IMRT, concomitant hormone treatment and patient related
factors (high BMI, large breast, smoking during treatment and the genetic variation in MLH1 rs1800734) were
associated with increased acute skin toxicity in patients receiving radiation therapy after breast-conserving
surgery. Trastuzumab seemed to be protective.
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Breast-conserving therapy with the adjuvant use of radio-
therapy (RT) has gained an established role in the
treatment for early-stage breast cancer with excellent
long-term local control and survival [1]. During or shortly
after the course of breast cancer RT, a large portion of the
patients will experience acute radiation dermatitis to some
degree, varying from mild to brisk erythema with or with-
out moist desquamation and occasionally ulceration of the
skin [2]. There is accumulating clinical evidence that acute
reactions are associated with the development of late tox-
icity: Lilla et al. showed that telangiectasia are in fact late
sequelae of moist desquamation and acute erythema is
shown to be a risk factor for poor cosmetic outcome [3-5].
Though the skin is not a dose-limiting tissue, skin toxicity
is associated with impairment of patients’ quality of life,
causes pain and discomfort and limits activities [2,6]. The
challenge is to minimize these side effects without losing
efficacy of the treatment.
Over the years, many attempts have been made to reduce
the number of patients experiencing acute skin toxicity and
inferior cosmetic outcome by introducing improved radi-
ation techniques, such as intensity-modulated radiotherapy
(IMRT). This technique has been shown to be superior
over conventional wedge-based whole breast irradiation by
delivering a more homogenous dose through the breast
and removing the radiation hot spots; it results in an ap-
proximately 20% reduction of the frequency of moist des-
quamation [6,7]. Large breast size significantly contributes
to dose inhomogeneity, hot spots and toxicity [7,8]. The
variation in clinical response is, however, only partly
explained by treatment factors such as radiation dose,
fractionation scheme, and concomitant therapies. Patient-
related features (e.g. bra cup size and body mass index
(BMI)) also play a role together with an unknown contri-
bution from genetic factors. Up to now there are no data
available to estimate directly the heritability of clinical ra-
diosensitivity based upon family history of radiotherapy
toxicity, but it is likely to be somewhat lower than for
chromosomal and cellular radiosensitivity, which have
been calculated to be 58-78% [9].
Acute toxicity is initiated by depletion of acutely respond-
ing epithelial tissues and damage to microvessels [10]. Nu-
merous studies have reported on genetic variations
modifying the clinical radiosensitivity risk, predominantly
in pathways based on mechanistic understanding of the ra-
diation pathogenesis (reviewed in [11]). In the present
study, single nucleotide polymorphisms (SNPs) in genes in-
volved in major DNA repair pathways (LIG3, XRCC3,
MLH1) and in regulatory regions that influence the expres-
sion levels of radioresponsive genes are considered [12-16].
To gain a better insight into the development of
radiation-induced dermatitis and moist desquamation, we
evaluated the association between patient and treatmentfeatures with these endpoints. The association between
SNPs and the different clinical endpoints was also studied.
Methods
The study population consists of 377 breast cancer patients
treated with adjuvant IMRT with curative intent after
breast-conserving surgery (stage T1-3, N0-1, M0). Of them,
282 breast cancer patients were treated at the Ghent Uni-
versity Hospital (GUH) and 95 patients were treated at
ST.-Elisabeth Clinic and Maternity (CMSE) in Namur. Pa-
tients’ follow-up ranged from 1 month after the end of RT
to 41 months after the end of RT (median = 18 months).
At GUH, patients were treated in prone or supine pos-
ition using a multi-beam IMRT technique in supine pos-
ition and a tangential 2-beam field-in-field IMRT technique
in prone position as described previously [17]. The whole
breast was treated with hypofractionated radiotherapy
(40.05 Gy in 15 fractions [18]) with 6-MV photons of an
Elekta Synergy linear accelerator (Crawley, United Kingdom).
An additional photon boost of 10 Gy in 4 fractions to the
tumour bed was given to 75% of the patients. For the
prone patient setup, a unilateral breast holder (Van De
Velde, Schellebelle, Belgium) and a prone breast board
(Orfit Industries) were used [19]. Twenty-two patients
were treated in prone position with voluntary moderate
deep inspiration breath hold. At CMSE Namur, a sliding
window tangential field-IMRT technique was used associ-
ated with moderate deep inspiration breath hold whenever
the primary beam intersected the heart as previously de-
scribed by Remouchamps et al. [20]. Patients with self-
reported bra cup size ≥D received normofractionated
radiotherapy (50.00 Gy in 25 fractions), women with bra
cup size < D received hypofractionation or normofractio-
nation according to the preference of the radiation on-
cologist (n = 28). More than 90% received an additional
boost of 10 Gy in 4 fractions with electron beams. Nodal
irradiation was performed by a complex multi-beam
IMRT or arc technique at GUH, at CMSE Namur, a one
point setup with 4 beams with dynamic intensity modula-
tion in the beams was used.
Adjuvant systemic therapy
Adjuvant hormone therapy, consisting of tamoxifen or
aromatase inhibitors, was administered in most pa-
tients concomitantly with IMRT. The others received
hormone therapy sequentially after IMRT. Patients who
received adjuvant chemotherapy, combination of antra-
cyclines and taxanes, completed chemotherapy before
IMRT, while trastuzumab was allowed concomitantly
with IMRT.
Data collection
Data on patients’ medical history, tumor and treatment
characteristics were collected prospectively. Table 1 gives
Table 1 Patient characteristics for patients treated at
GUH and CMSE Namur
GUH CMSE Namur
(n = 282) (n = 95)
Age (years)
Median 57.5 59.0
Range 30-82 35-82
Bra cup size
Small A 13 (4.6) 3 (3.2)
B 85 (30.2) 33 (34.7)
C 101 (35.8) 34 (35.8)
Large D 53 (18.8) 16 (16.8)
E 16 (5.7) 5 (5.3)
F 7 (2.5) 3 (3.2)
G + H 2 (0.6) 1 (1.0)
Missing 5 0
BMI
Median 25.5 26
Range 16-50 16-38
Missing 2 0
Menstruation
No 235 (83.3) 76 (80.0)
Yes 45 (16.0) 18 (18.9)
Missing 2 1
Smoking
during RT
No 244 (86.5) 79 (83.2)
Yes 35 (12.4) 16 (16.8)
Missing 3 0
Diabetes
No 254 (90.1) 84 (88.4)
Yes 22 (7.8) 11 (11.6)
Missing 6 0
Hypertension
No 196 (69.5) 66 (69.5)
Yes 81 (28.7) 29 (30.5)
Missing 5 0
Fractionation
Normo 0 45 (47.4)
Hypo 282 50 (52.6)
Missing 0 0
Treatment
position
Supine 195 (69.1) 95 (100.0)
Prone 87 (30.9) 0
Missing 0 0
Table 1 Patient characteristics for patients treated at
GUH and CMSE Namur (Continued)
GUH CMSE Namur
(n = 282) (n = 95)
Boost
No 64 (22.7) 7 (7.4)
Yes 218 (77.3) 88 (92.6)
Missing 0 0
Nodal irradiation
No 241 (85.5) 87 (80.6)
Yes 41 (14.5) 21 (19.4)
Missing 0 0
Hormonal
therapy
No 46 (16.3) 25 (26.3)
Concomitant 236 (83.7) 7 (7.4)
Sequential
(after IMRT)
0 63 (66.3)
Missing 0 0
Chemotherapy
No 188 (66.7) 55 (57.9)
Yes 94 (33.3) 40 (42.1)
Missing 0 0
Trastuzumab
No 257 (91.1) 83 (87.4)
Yes 25 (8.9) 12 (12.6)
Missing 0 0
Abbreviations: GUH Ghent University Hospital, CMSE ST.-Elisabeth Clinic and
Maternity, BMI Body Mass Index.
Data are given as no. (%) unless otherwise indicated.
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Acute toxicity was assessed weekly during treatment
and at 1–2 weeks after treatment. The reported toxicity
represents the maximal reported acute toxicity, either
during or after completion of IMRT. Acute dermatitis
was documented according to a standard protocol using
the Common Terminology Criteria for Adverse Events
(CTCAE) v3.0 scoring system. This grades patients with
mild erythema or dry desquamation as 1, moderate to
brisk erythema or patchy moist desquamation mostly
confined to the skin folds as 2 and confluent moist des-
quamation as 3. Desquamation was scored separately on
a 3-point scale (0-none, 1-dry, 2-moist). Grade 2–3 tox-
icity was considered clinically relevant and was included
in the analysis. Genomic DNA was isolated from a fresh
blood sample taken before start of radiotherapy, using the
Puregene genomic DNA purification kit (Gentra Systems,
Minneapolis, MN). The study was approved by the local
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424, EC 2009/184) and all study patients provided written
informed consent.
Selection of candidate genes/polymorphisms and
genotyping
Eight candidate polymorphisms were selected for genotyp-
ing (Table 2). Of these, five SNPs (rs3888929, rs4867592,
rs7970524, rs12003093, rs4760658) were chosen as they pu-
tatively affect the expression levels of radiation-responsive
genes directly, or by trans effects, based on genetic linkage
and association analysis as described previously by Smirnov
et al. The authors suggested that those regulatory vari-
ants might be able to contribute to the development of
genetic tools for radiosensitivity [16]. The other SNPs
were chosen based on their previous association with tox-
icity induced by radiotherapy or methylating agents
(XRCC3 rs861539, LIG3 rs3744355, MLH1 rs1800734)
[12-15]. Genotyping was performed using restriction frag-
ment length polymorphism analyses, high resolution melt-
ing curve analyses, single base extension techniques or
direct sequencing. For reproducibility control, 15% of all
samples were duplicated. The concordance rate between
duplicate samples was 100%. Primers details are available
on request. Tests for deviation from Hardy-Weinberg
equilibrium, for the entire sample showed that the
rs4867592 SNP had a p-value <0.0001 and was excluded
from further analyses.
Statistical analysis
The studied endpoints were development of acute radiation-
induced dermatitis (CTCAE G2+) and moist desquamation.
For the clinical association analysis, univariate analysis
was initially carried out to assess the relationship between
patient- (age, bra cup size (A + B + C vs. ≥D), BMI, men-
struation, smoking during RT, diabetes, hypertension) and
treatment-related factors (fractionation scheme, treatment
position, boost dose to tumour bed, nodal irradiation,
hormone therapy, chemotherapy and trastuzumab) and
the endpoints. Patients with and without G2+ acute skinTable 2 Characteristics of the SNPs
Gene or gene regulator rs number MAF* Nucleotide substitu
LIG3 rs3744355 9.1 G > C
MLH1 rs1800734 22.6 G > A
XRCC3 rs861539 39.0 C > T
PHLDA3 rs3888929 30.3 G > A
LCP2 rs4867592 19.1 C > A
LTHA4 rs7970524 25.1 T > C
NDUFB6 rs12003093 23.4 A > G
VDR rs4760658 36.6 A > G
*Minor allele frequency in Caucasian population.toxicity were compared by means of the Mann–Whitney
test for continuous variables and the χ2-test for cat-
egorical variables. Power calculations were performed
with Power for Genetic Association analyses [21]. For
these we took into account: the incidence of derma-
titis (58%) or moist desquamation (15%) observed in
our cohort, the lowest minor allele frequency (9%) of
the considered SNPs, a probability adjusted by the
number of SNPs (α = 6.25 × 10−3) under a dominant
genotypic test, and a genotype relative risk of ≥1.5.
This resulted in a power of 94.3% for acute dermatitis
and 60.9% for moist desquamation. To assess the inde-
pendent effect of each polymorphism, unconditional lo-
gistic regression analyses were performed to calculate
crude ORs. The Benjamini-Hochberg (BH) procedure was
used to control for multiple testing (i.e. 43 tests per end-
point: 28 genetic and 15 clinical parameter tests) to reduce
the risk of finding false-positive associations. Variables
with p < 0.05 were tested in a multivariate logistic regres-
sion analysis. Statistical analyses were performed using
SPSS 17.0 software (SPSS Inc., Chicago, IL). R library
multtest (http://www.r-project.org/) was used to perform
the multiple testing analyses.
Results
Acute radiation-induced skin toxicity data were available
for all 377 patients. Two-hundred twenty patients (58%)
developed G2+ dermatitis. The occurrence of dermatitis
did not differ between both centres (GUH: 57% (162/282),
CSME: 61% (58/95)). Moist desquamation (patchy or con-
fluent) occurred in 56 patients (15%) and differed between
both centres: 10% of the patients treated at GUH and 30%
of the patients treated at CMSE (p < 0.001).
Acute radiation-induced skin toxicity
Table 3 depicts the parameters associated with acute
G2+ dermatitis, in univariate analysis. Bra cup size ≥D
(p < 0.001), BMI (p < 0.001) and smoking during RT (p =
0.029) were associated with the development of G2+
dermatitis. Irradiation of the nodal region (p = 0.006) andtion Genomic location Amino acid substitution Reference
5′-flanking - [12,13]
5′-UTR - [14]
Coding Thr241Met [15]
Unknown - [16]
Unknown - [16]
5′-flanking - [16]
Unknown - [16]
Intronic - [16]
Table 3 Associations between patient- and therapy-related characteristics and acute G2+ dermatitis
All
(n = 377)
G0-1
(n = 157)
G2+
(n = 220)
p-value pBH-value
Bra cup size
A + B + C 269 (71.4) 130 (48.3) 139 (51.7)
≥D 103 (27.3) 26 (25.2) 77 (74.8) <0.001 0.001
BMI
Median 26 24 26
Range 16-50 16-37 16-50 <0.001 0.001
Smoking during RT
No 323 (85.7) 141 (43.7) 182 (56.3)
Yes 51 (13.5) 14 (27.5) 37 (72.5) 0.029 0.156
Fractionation
Normo 45 (11.9) 6 (13.3) 39 (86.7)
Hypo 332 (88.1) 151 (45.5) 181 (54.5) <0.001 <0.001
Treatment position
Supine 290 (76.9) 108 (37.2) 182 (62.8)
Prone 87 (23.1) 49 (56.3) 38 (43.7) 0.002 0.019
Nodal irradiation
No 315 (83.6) 141 (44.8) 174 (55.2)
Yes 62 (16.4) 16 (25.8) 46 (74.2) 0.006 0.037
Hormonal therapy
No 71 (18.8) 39 (54.9) 32 (45.1)
Concomitant 243 (64.5) 94 (38.7) 149 (61.3)
Sequential (after IMRT) 63 (16.7) 24 (38.1) 39 (61.9) 0.041 0.207
Hormones (concomitant)
Tamoxifen 155 62 (40.0) 93 (60.0)
Aromatase inhibitor 85 32 (37.6) 53 (62.4)
Chemotherapy
No 243 (64.5) 92 (37.9) 151 (62.1)
Yes 134 (35.5) 65 (48.5) 69 (51.5) 0.045 0.215
Trastuzumab
No 340 (90.2) 133 (39.1) 207 (60.9)
Yes 37 (9.8) 24 (64.9) 13 (35.1) 0.003 0.026
Abbreviations: G CTCAEv.3 grade, BMI Body Mass Index; pBH = corrected p-value by Benjamini-Hochberg procedure.
Data are given as no. (%) unless otherwise indicated. P<0.05 is considered significant and is showed in bold.
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also associated with an increased risk of acute derma-
titis, with no difference in incidence between aromatase-
inhibitors and tamoxifen. In contrast, patients receiving
trastuzumab or having received chemotherapy seem to be
less prone to the development of RT-induced acute
dermatitis (p = 0.003 and p = 0.045, respectively). Further-
more, patients treated with hypofractionated radiotherapy
develop less dermatitis when compared to patients treated
in the normofractionated regimen (p < 0.001). And, pa-
tients treated in prone position developed less dermatitis
than patients treated supine (p = 0.002). In multivariateanalysis, chemotherapy and nodal irradiation were no lon-
ger significant (Table 4).
For moist desquamation, univariate significant associa-
tions were found with bra cup size ≥D (p < 0.001), BMI
(p < 0.001), normofractionation (p < 0.001), supine posi-
tioning (p = 0.002), concurrent hormone therapy (p = 0.004)
and CSME center (p < 0.001) (Table 5). In multivariate ana-
lysis (Table 6), bra cup size ≥D, BMI, fractionation and hor-
mone therapy remained statistically significant. Treatment
center was no longer significantly associated with moist
desquamation due to the fact that the normofractionated
schedule was only prescribed at CMSE.
Table 4 Multivariate analysis for G2+ dermatitis and moist desquamation
Clinical/genetic factor Acute G2+ dermatitis Moist desquamation
OR p-value OR p-value
Center (CMSE vs. GUH) - - 3.206 0.158
BMI 1.088 0.003 1.170 <0.001
Bra cup size (cup≥ D vs. cup A + B + C) 2.833 0.001 2.146 0.043
Smoking (yes vs. no) 2.711 0.010 - -
Fractionation (hypo vs. normo) 0.083 <0.001 0.096 <0.001
Treatment position (prone vs. supine) 0.399 0.004 0.373 0.074
Hormone therapy
No 1 1
Concomitant 3.207 0.001 4.770 0.037
Sequential (after IMRT) 1.003 0.994 1.078 0.901
Nodal irradiation (yes vs. no) 1.975 0.100 - -
Chemotherapy (yes vs. no) 0.954 0.877 - -
Trastuzumab (yes vs. no) 0.177 <0.001 - -
MLH1 rs1800734 G > A
GG 1 -
GA 0.492 0.008 - -
AA 0.537 0.232 - -
Abbreviations: GUH Ghent University Hospital, CMSE Clinic Maternity Sainte-Elisabeth, BMI Body Mass Index, MLH1 MutL protein homolog 1.
P<0.05 is considered significant and is showed in bold.
Table 5 Associations between patient- and therapy-related characteristics and moist desquamation
All patients
All
(n = 377)
No
(n = 321)
Yes
(n = 56)
p-value pBH-value
Bra cup size
A + B + C 269 (71.4) 242 (90.0) 27 (10.0)
≥D 103 (27.3) 76 (73.8) 27 (26.2) <0.001 0.001
BMI
Median 26 25 29
Range 16-50 16-40 21-50 <0.001 <0.001
Fractionation
Normo 45 (11.9) 22 (48.9) 23 (51.1)
Hypo 332 (88.1) 299 (90.1) 33 (9.9) <0.001 <0.001
Treatment position
Supine 290 (76.9) 239 (82.4) 51 (17.6)
Prone 87 (23.1) 82 (94.3) 5 (5.7) 0.002 0.019
Hormonal therapy
No 71 (18.8) 62 (87.3) 9 (12.7)
Concomitant 243 (64.5) 214 (88.1) 29 (11.9)
Sequential (after IMRT) 63 (16.7) 45 (71.4) 18 (28.6) 0.004 0.029
Hormones (concomitant)
Tamoxifen 155 139 (89.7) 16 (10.3)
Aromatase inhibitor 85 74 (87.1) 11 (12.9)
Abbreviations: GUH Ghent University Hospital, CMSE Clinic Maternity Sainte-Elisabeth, BMI Body Mass Index; pBH = corrected p-value by Benjamini-Hochberg procedure.
Data are given as no. (%) unless otherwise indicated. P<0.05 is considered significant and is showed in bold.
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Table 6 Effect of MLH1 rs1800734 on radiotherapy acute skin reactions
Acute G2+ dermatitis Moist desquamation
G0-1
(n = 157)
G2+
(n = 220)
OR p-value pBH-value No
(n = 321)
Yes
(n = 95)
OR p-value pBH-value
MLH1 rs1800734
G > A GG 81 (51.6) 146 (66.4) 189 (58.9) 38 (67.9)
GA 64 (40.8) 60 (27.3) 0.52 0.004 0.029 110 (34.3) 14 (25.0) 0.63 0.172 0.477
AA 9 (5.7) 12 (5.5) 0.74 0.514 0.804 17 (5.3) 4 (7.1) 1.17 0.788 0.915
Missing 3 (1.9) 2 (0.9) 5 (1.6) 0
GG vs. GA + AA (dominant) 0.55 0.005 0.033 0.71 0.257 0.575
GG + GA vs. AA (recessive) 0.94 0.889 0.936 1.35 0.600 0.860
Abbreviations: MLH1 MutL protein homolog 1, pBH = corrected p-value by Benjamini-Hochberg procedure.
Data are given as no. (%) unless otherwise indicated. P<0.05 is considered significant and is showed in bold.
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The only significant p-value, in univariate analysis, was for
acute radiation-induced dermatitis with the GA genotype
of rs1800734 in the MLH1 gene with a BH-adjusted p-
value of 0.029 (Table 6). Adjusting for above mentioned
factors by multivariate regression analysis had no effect on
the statistically significant association. None of the other
SNPs had any effect on the risk of acute skin toxicity.
Discussion
This study was performed to analyze the influence of
treatment and patient-related factors on the develop-
ment of acute radiation-induced skin toxicity. Bra cup
size, BMI, smoking, treatment position, choice of RT
schedule and the administration of adjuvant therapies
seem to contribute to the variability in radiation skin
toxicity. Also, the MLH1 rs1800734 SNP was found to
be significantly associated with the development of acute
dermatitis.
Our data support the hypothesis that acute toxicity
does not increase with moderate hypofractionation [22].
In fact, the occurrence of acute skin toxicity was signifi-
cantly higher among patients treated with normofractio-
nation compared to the hypofractionated schedule.
There are only few reports studying hypofractionation in
overweighed or large-breasted patients [23,24]. We ob-
serve a 20% decrease in dermatitis and an even larger
decrease (70%) in moist desquamation in large-breasted
patients treated in supine position with hypofractiona-
tion compared to normofractionation (data not shown).
Bra cup size and BMI were also confirmed as significant
risk factors for the development of acute skin toxicity,
in accordance with the majority of published reports
[7,8,25-27]. Both are measures of breast volume as BMI
was previously found to be strongly correlated with breast
volume [27]. The association between larger breast vol-
ume and toxicity is thought to be due to dose inhomo-
geneity, high dose regions, and the bolus effect in theinframammary and axillary regions [8]. Due to the un-
availability of dose homogeneity and hot spot data for the
complete dataset, we were unable to test this for the total
patient population, but the hypothesis is confirmed in a
subset of the population [19]. Goldsmith et al. show that
dose inhomogeneity is insufficient to explain the associ-
ation and other factors like the presence of more adipose
tissue might also play a role [25]. In prone position, the
skin creases disappear, dose homogeneity is improved and
hot spots are reduced leading to a reduction in acute skin
toxicity [17]. In this study, we found a decrease in radio-
dermatitis and moist desquamation in patients treated
with prone-IMRT. Especially patients with large breast
sizes are expected to have a great benefit from prone-
IMRT as shown by Mulliez et al. [19].
In this study, two types of adjuvant hormone therapy,
tamoxifen or aromatase-inhibitors, were concurrently ad-
ministered with radiotherapy to hormone receptor posi-
tive breast cancer patients. Present data show that use of
hormone therapy is, regardless the type, associated with
an increase in radiation-induced dermatitis. This is in ac-
cordance with a previous study investigating the effect of
tamoxifen on acute skin reactions [26]. But in contrary
with the COHORT randomized trial, that shows no differ-
ence between concurrent and sequential administration of
letrozole; the latter was administered 3 weeks after RT
when it is supposed that the radiosensitising effect of
endocrine therapy is minimal [28]. Concurrent adminis-
tration of trastuzumab and IMRT was found to be associ-
ated with lower rates of acute dermatitis in the present
study. This finding needs to be put in perspective as it is
in contradiction with the observation of a large random-
ized study that could not find a difference in acute toxicity
[29]. Longer follow-up will be necessary to observe the ef-
fect of concurrent administration on cardiac toxicity.
Our study shows an association between the MLH1
rs1800734 SNP and lower rates of acute radiation-induced
dermatitis: heterozygotes are less present in the G2+
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of the MLH1 transcription site in the core promoter, a re-
gion essential for maximum transcriptional activity [30].
The SNP was previously shown to be associated with
acute myeloid leukemia after methylating chemotherapy
for Hodgkin disease [15]. MLH1 gene encodes MutL
protein homolog 1 which is involved in DNA mis-
match repair. Suga et al. found statistically significant
associations with rs3744355 in the 5′ flanking region
of the LIG3 gene and acute radiation-induced skin re-
actions in the Japanese population and Murray et al.
provided replicated evidence for this association in a
European Caucasian population [12,13]. We, however,
could not confirm this association. Smirnov et al. hy-
pothesized that regulatory variants might be able to
contribute to the development of genetic tools to pre-
dict for radiosensitivity [16]. This could not be dem-
onstrated in our study population.
Radiation-induced dermatitis includes erythema, edema,
dry and moist desquamation as symptoms of inflam-
mation probably triggered by cell death [31]. One of
the shortcomings in this study is the fact that erythema
was not measured objectively with a colorimeter. As the
CTCAE criteria are based on subjective scoring, the
difference between mild, moderate and brisk erythema is
observer-dependent. This probably explains the large
number of patients developing G2+ acute dermatitis when
compared to other reports. A strength of our investigation
is the nearly complete data set for a relatively large num-
ber of patients enrolled. Furthermore, patient recruitment
as well as clinical outcome data collection were carried
out prospectively. Although the associations hold after
correcting for multiple testing, the results of this study
should be validated in an independent study.
Conclusion
A number of treatment and patient related factors are
identified that modify the risk for the development of
acute skin toxicity after whole-breast IMRT. Large bra
cup, BMI, normofractionation and concomitant hor-
mone therapy contribute to the development of moist
desquamation. Patient related factors (high BMI, large
breast, smoking during treatment and the genetic vari-
ation MLH1 rs1800734), choice of RT schedule and the
administration of adjuvant therapies affect the develop-
ment of radiodermatitis.
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